# Toward Personalized Anticoagulation: Clinical Predictors of Early Warfarin Response in Heart Valve Replacement Patients

**Authors:** Rania Abdel-latif, Shaban Mohammed, Tamer Abdalghafoor, Rana Mekkawi, Cornelia Sonia Carr, Abdulaziz M. Alkhulaifi, Ali Kindawi, Mohd Lateef Wani, Samim Azizi, Mohamad El-Kahlout, Sankar Balasubramanian, Hatem Sarhan, Samy Hanoura, Sameh Aboulnaga, Yasser Shouman, Abdulwahid Al Mulla, Radja Badji, Wadha Al-Muftah, Amr Salah Omar

PMC · DOI: 10.3390/biomedicines14020446 · Biomedicines · 2026-02-17

## TL;DR

This study identifies clinical factors like valve position and baseline INR that affect early warfarin response in heart valve replacement patients, aiming to improve personalized dosing.

## Contribution

The study introduces a prediction model for initial warfarin dosing in heart valve replacement patients based on clinical predictors.

## Key findings

- Mitral valve recipients required lower warfarin doses but had higher INR overshoot rates compared to aortic or double valve groups.
- Female sex and higher baseline INR were associated with greater warfarin sensitivity.
- The prediction model explained ~28% of dose variance, showing moderate performance in initial dosing.

## Abstract

Background/Objective: Warfarin is the standard anticoagulant for patients with mechanical heart valve replacement (HVR). However, its narrow therapeutic index and interpatient variability complicate early postoperative management. Evidence on how valve position influences warfarin sensitivity is limited. This study evaluated the impact of prosthetic valve position and clinical factors on early warfarin response and developed a prediction model to guide initial warfarin dosing in HVR patients. Methods: A retrospective study was conducted on 310 adults who underwent mechanical aortic, mitral, or double valve replacement at Hamad Medical Corporation (2015–2022). Warfarin was initiated within 24 h postoperatively, and patients were monitored for three days. Outcomes included daily warfarin dose, international normalized ratio (INR) levels, attainment of therapeutic INR, INR overshoot (≥4), and the warfarin dose index on day 3 (WDI3). Predictors of WDI3 were analyzed using multivariable regression, and a LASSO model was applied to a dose prediction algorithm for the day 1 dose. Results: Mitral valve recipients required lower doses than aortic or double valve groups (p = 0.008) but had higher INR overshoot rates (18.75% vs. 16.05% and 4.55%; p = 0.033). Female sex and a higher baseline INR were associated with greater sensitivity (p < 0.01), whereas mitral/double valve position predicted reduced sensitivity (p = 0.010). Only half of the cohort reached therapeutic INR by day 3. The prediction model explained ~28% of dose variance with moderate performance. Conclusions: Valve position, sex, and baseline INR significantly influence early postoperative warfarin response. Incorporating these clinical factors into dosing algorithms may optimize initial warfarin management in HVR patients.

## Linked entities

- **Chemicals:** Warfarin (PubChem CID 54678486)

## Full-text entities

- **Genes:** GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}
- **Diseases:** inflammatory (MESH:D007249), hepatic dysfunction (MESH:D008107), degenerative valve disease (MESH:D019636), injury to (MESH:D014947), rheumatic fever (MESH:D012213), HVR (MESH:D006349), stroke (MESH:D020521), hypoalbuminemia (MESH:D034141), hemorrhagic (MESH:D006470), MVR (MESH:D008944), thrombotic (MESH:D013927), cardiovascular disorder (MESH:D002318), thromboembolic (MESH:D013923), Heart failure (MESH:D006333)
- **Chemicals:** Enoxaparin (MESH:D017984), MVR (-), rifampin (MESH:D012293), vitamin K (MESH:D014812), amiodarone (MESH:D000638), Warfarin (MESH:D014859)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938066/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938066/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938066/full.md

---
Source: https://tomesphere.com/paper/PMC12938066